Cogent Biosciences now has three bezuclastinib NDAs under FDA review
Cogent now has three bezuclastinib NDAs under FDA review, with GIST and non-advanced mastocytosis decisions due before year-end.
Pharma & Biotech
Pharma & Biotech
Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.